Safety and Antiviral Activity of Short-Duration Combinations of the Investigational Small Interfering Ribonucleic Acid VIR-2218 with the Neutralizing, Vaccinal Monoclonal Antibody VIR-3434: Post-Treatment Follow-Up from the Phase 2 MARCH Trial